» Articles » PMID: 39441777

Preferences for Oral and Injectable PrEP Among Qualitative Sub-study Participants in HPTN 084

Abstract

Background: HPTN 084 compared the safety and efficacy of long-acting injectable cabotegravir (CAB) to daily oral TDF/FTC for prevention of HIV-1 in uninfected African women. Like a similar trial in MSM/TGW (HPTN 083), the trial was stopped early for efficacy, expediting the need to consider introduction strategies for different populations. We examine survey and qualitative data from a four-country sub-study to examine oral and injectable PrEP acceptability and considerations for CAB access among African women.

Methods: Participants completed baseline and follow-up surveys on HIV risk perception, sexual behavior. product acceptability and adherence during the blinded trial. Additionally, up to two in-depth interviews each with 73 sub-study participants explored product use and trial-related experiences, during the blinded and unblinded study periods. Using survey data, we classified participants as: engaged in female sex work (FSW), having multiple non-transactional partners, or monogamous. A study statistician identified participants' assigned study arm. We followed a thematic analysis process to read transcripts, develop a codebook and apply codes in NVivo to transcripts with intermittent intercoder reliability checks; using Excel matrices to explore differences across risk categories and study arms.

Findings: Participants overwhelmingly preferred injections to pills, appreciating the ease, convenience, and privacy of a long-acting formulation. Many participants described challenges with contraceptive and/or study pill adherence, impeded by late night work, unexpected travel, or heavy drinking. Women in the TDF/FTC arm were more likely to describe side effects, compared to those in the CAB arm. Pain also varied widely by study arm. When considering post-trial access to CAB, limited PrEP knowledge, cost and concerns around stigma and poor service quality were potential access barriers.

Conclusion: Women's desire for privacy and ease of use outweighed injectable concerns, resulting in a strong preference for CAB. Cost and accessibility will need to be addressed by implementation programs.

Citing Articles

Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.

Baker D, Collins L, Cantos V, Hollenberg E, Kaplan A, Cowan T J Gen Intern Med. 2025; .

PMID: 39934566 DOI: 10.1007/s11606-025-09350-8.

References
1.
Delany-Moretlwe S, Lombard C, Baron D, Bekker L, Nkala B, Ahmed K . Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018; 18(11):1241-1250. DOI: 10.1016/S1473-3099(18)30428-6. View

2.
Marrazzo J, Tao L, Becker M, Leech A, Taylor A, Ussery F . HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. JAMA. 2024; 331(11):930-937. PMC: 10951736. DOI: 10.1001/jama.2024.0464. View

3.
Venter W . Pre-exposure Prophylaxis: The Delivery Challenge. Front Public Health. 2018; 6:188. PMC: 6043793. DOI: 10.3389/fpubh.2018.00188. View

4.
Tolley E, Li S, Zangeneh S, Atujuna M, Musara P, Justman J . Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J Int AIDS Soc. 2019; 22(10):e25408. PMC: 6813716. DOI: 10.1002/jia2.25408. View

5.
Headley J, Lemons A, Corneli A, Agot K, Ahmed K, Wang M . The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa. PLoS One. 2014; 9(9):e106410. PMC: 4167553. DOI: 10.1371/journal.pone.0106410. View